Hello
OpPacli™
Novel chemo for solid cancers
(lung, breast, etc.)
well
better
for long
A 3B USD opportunity
Problem – Cytotoxic drugs are indispensable components of the anticancer arsenal. Chemo sadly remains a neglected area of oncology research despite its brutal adverse effects and perfectible efficacy - it is there to stay. 16 B USD worth of cytotoxic drugs are administered each year under a maximum tolerated dose regimen; paclitaxel itself (Taxol®, Abraxane®) is a 3 B$ neglected market crying for a radical upgrade.
Solution – OpPacli™ will provide patients with an efficacious and bearable chemo treatment. Silica's versatile chemistry allows our nanocarrier to mend three faults of current treatments by:
- sequestering its toxic cargo away from healthy tissues during circulation,
- unloading more of the cancer-killing drug in the tumor microenvironment and
- exiting the body with minimal impact on the patient.
Treat solid cancers well
to be better off
and live for long
Novel chemotherapy
Pharma in silica, a preclinical-stage pharmaceutical company, develops a bearable, efficacious and affordable chemotherapy for solid cancers.
The OpPacli™ nanocarrier, a nano-sized silica sphere, has been designed to increase the efficacy and reduce the toxicity of chemotherapies used daily to treat certain cancers (annual sales > 3 B USD, growing).
Us, shareholders and scientists, have made a triple wager. We trust that, in 2027, our novel silica-based chemo will:
- reduce the adverse effects and improve the survival of persons treated for a cancer;
- be licensed by several pharmaceutical companies;
- provide the investors wiith a profitable exit.
Production of preclinical and clinical lots in Pharma in silica's NanoLab
First unmet need: lung cancer
Among the deadliest (1,7 M/y)
5-year survival: 26% (advance-stage: 8%)
25%~40% response to immunotherapies
Chemo first choice for patients with low PD-L1 expression
A superior nanocarrier...
Entrapped paclitaxel
Cytotoxic cargo sequestered in the particle's porous network
Silica matrix
Proprietary combination of silanes (regulator-accepted excipients)
Functionality
Surface treatment for stability, stealth in blood, cell internalization, in situ drug release
Add-on ready
Anchoring points for third-party targeting ligands or other useful function
... builds unique value
OpPacli's novel pharmacokinetics
Less drug in healthy tissues, long circulation, more drug to the tumor
lead to novel pharmacodynamics
Reduced adverse effects, increased efficacy
that procure benefits to patient
Extended survival rate, improved quality of life, savings for payer, patient & insurer
and trigger creation of value
Pharma deals, profitable exit
Timeline: well defined path to IND/CTA
Launch, POCs
Paclitaxel-loaded nanoparticle
Patents filed
Own R&D facility
Innocuity & efficacy demos
Technology
Lead candidate: OpPacli™ • 505 (b) (2)
Continuous flow production with in-process QC
Scaled-up regulatory-compliant CMC
Patents in national phase or issued
CROs recruited
Preclinical studies
4 M CAD round
Comparative murine xenograff studies
Reg. studies (CRO)
IND/CTA filing
Clinical lot production
Development of proprietary prototypes
Intelligence toward pharma partnerships
Clinical trial
Phase I/IIa OpPacli™ vs NSCLC (USA/Can)
Basket study - OpPacli vs breast & other solid tumors
Development of novel products
Inflection point
1st pharma partnership (license & contract manufacturing)
Exit opportunities (M&A & IPO) and/or profitable operations
Growth
Early-stage dev. of proprietary products
Additional pharma partnerships
License and contract manufacturing
Own GMP production facility
4 M CAD preclinical round
A 4 M CAD round is on-going.
The first tranche was closed in August 2024 when historical shareholders and new accredited investors brought in 1,5 M$.
This Autumn, participate to the second 2,5 M$ tranche at the same price & conditions, half of which to be matched by IQ.
The capital will be dedicated, for the next 18 months, to:
- complete the preclinical studies up to an approved USA/Canada phase I/IIa study for our 3rd generation nano-paclitaxel against Non-Small Cell Lung Carcinoma (NSCLC);
- approach pharma partners toward licences and manufacturing contracts;
- conduct 3 proofs of concept;
- upgrade to clinical standards our in-house production capability.
Exit opportunities 2027
M&A, IPO and/or profitable operations from pharma partnerships
Median upfront payment by pharmas paid in Q1-3 2024: 27 M USD for a phase I license
Invest now
Same conditions & price than 1st tranche
All shares voting and participating
Term sheet, pre-IND package & due diligence reports available upon request
Pharma in silica recruits
Experienced clinicians : phase I/IIa study OpPacli™ vs NSCLC
Solid cancer oncologists, preferably in thoracic oncology • Sensitive to the impact of chemotherapy side effects on the patient experience and healthcare system • Willing to comment the draft clinical program and to share their experience during an exploratory meeting • Eventually, ready to contribute to the clinical study.
Experts in chemotherapy : advisory committee
Motivated by the reduction of chemotherapy side effects • Well-versed in the measurement of patient experience and the pharmaco-economics of chemo • Ideally with experience and/or curiosity for nanocarriers.
Contact
François Arcand
info@pharma-insilica.com
OpPacli™ vs solid cancers
About us
President & cofounder
François Arcand, MBA
Co-founder of Medicago (Québec), CEO of ERA Biotech (Barcelona)
Scientific coordinator
Myriam Laprise-Pelletier, PhD
Nanomedicine research at Université Laval (Québec)
Contact us
info@pharma-insilica.com
2500, Parc-Technologique Blvd
Quebec City (Quebec) G1P 4S6
Canada
Product Development
Sonia Trepanier, PhD
VP, Product Dev., Medicago & Aramis
Business Development
Jean-François Haince, PhD
Oncology R&D/business dev. & tech transfer
Medical Director
(Q1 2025)
Oncologist expert in chemo & early-stage drug development
Experienced management & top tier advisors
Expert chemists, pharmacists & technicians
Strong board of directors & networked investors (AbbVie, Pfizer, Roche, business, manufacturing, chemistry & startup)
News
To be up to date with Pharma in silica, visit us again ...
... or follow our LinkedIn page!
4 M$ investment agreement to prepare the clinical study of an improved chemotherapy
October 30th, 2024
Opening of the 2nd tranche of OpPacli™'s preclinical round
October 30th, 2024
First patents granted to Pharma in silica
January 29th, 2024
Pharma in silica receives positive feedback from FDA and Health Canada, paving the way for OpPacli™ clinical trials
November 20th, 2023
$ 2M toward an efficient and lenient chemotherapy: the government of Québec and 6 individual investors enter the capital of Pharma in silica
May 2nd, 2023
Ms. Isabelle Tremblay joins the board of directors of Pharma in silica
December 28th, 2022
Pharma in silica acquires the founding intellectual property on the OpKemo technology
July 29th, 20232
Pharma in silica launches its first preclinical program
June 1st 2022
Pharma in silica's scientific coordinator takes up her post
April 15th, 2022
Conclusion of the OptiSpheres 3 program
July 15th, 2021
Pharma in silica inaugurates its new high-safety laboratory
November 4th, 2020
The City of Québec financially supports Pharma in silica
February 3rd, 2020
Mr Bertrand Bolduc joins Pharma in silica inc.'s board of directors
November 18th, 2019
For a safe chemotherapy: Pharma in silica starts up
August 30th, 2019